Search Results for: azrx

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has announced that it will present at the upcoming Microcap Rodeo Winter Wonderland Conference. The virtual conference is slated for Feb. 16–19, 2021. AzurRx CEO James Sapirstein is scheduled to make a live company presentation during the conference. The AzurRx presentation … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Microcap Rodeo Winter Wonderland Conference”

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced its entry into an agreement with PPD Inc. (NASDAQ: PPD ), a leading global contract research organization (“CRO”), for its planned Phase 2 clinical trial evaluating a proprietary formulation of micronized niclosamide as … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Collaboration for Planned Phase 2 Clinical Trial of FW-1022”

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has announced that its CEO James Sapirstein will present at the virtual BIO CEO & Investor Digital Conference. The conference is slated for Feb. 16–18, 2021. During the online event, all registered attendees will be able to access Sapirstein’s presentation on … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in BIO CEO & Investor Digital Conference”

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, announced that it has completed patient enrollment in the first cohort of its Phase 2b OPTION 2 extension study. The study is evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in First Cohort of MS1819 Study”

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has added two clinical trial sites for the extension arm of its MS1819 Phase 2b OPTION 2 study. The study is investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). The additional … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Addition of Two Clinical Trial Sites for MS1819 Phase 2b OPTION 2 Extension Study”

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, has begun its Phase 2b OPTION 2 extension study of MS1819. AZRX announced that the first two patients have been dosed in the extension study of MS1819, which uses immediate release capsules for the treatment of … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Beginning of MS1819 Extension Study with Initial Dosing of Two Patients”

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, announced that it, along with First Wave Bio Inc., has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”). The notice of allowance is for issuance of a patent that covers … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX), First Wave, Receive Notice of Allowance for Niclosamide Patent”

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today issued a letter to its shareholders and the investment community from its CEO and President James Sapirstein. The letter discusses AzurRx BioPharma’s optimism and enthusiasm for 2021 and its extraordinary accomplishments in the face of so many … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Issues Letter to Shareholders”

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the upcoming Biotech Showcase Digital 2021 conference. The multiday event is scheduled for Jan. 11–15, 2021. As part of the company’s planned participation, AzurRx president and CEO James Sapirstein, along with other members of the senior management team, … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Biotech Showcase Digital 2021 Conference”

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it will participate in the virtual H.C. Wainwright BioConnect Conference taking place on Jan. 11-14, 2021. According to the update, AzurRx BioPharma president and CEO James Sapirstein will take part in virtual one-on-one meetings with … Continue reading “QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in H.C. Wainwright BioConnect Virtual Conference”